Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vutrisiran in transthyretin amyloidosis with cardiomyopathy
NL-OMON59481Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Vutrisiran with Placebo (2 arms). Primary endpoint: Composite of all-cause mortality and recurrent cardiovascular events. Started Oct 2020; status: completed.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON59481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59481.